
Opinion|Videos|April 30, 2025
Future Directions in BPDCN Treatment
Author(s)Hetty E. Carraway, MD
An expert discusses how addressing unmet needs in early diagnosis, treatment options, and long-term management, alongside exploring targeted therapies, combination approaches, and advancements in stem cell transplantation, holds promise for more effective and less toxic treatments for blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Advertisement
Episodes in this series

Summary for Physicians:
1. Unmet Needs in Managing BPDCN:
- Early Diagnosis: BPDCN is often diagnosed late, leading to poorer outcomes. Improved early detection methods are needed.
- Treatment Options: Limited effective therapies are available, and there is a need for more targeted, less toxic treatments.
- Long-Term Management: Few strategies exist for managing long-term remission and preventing relapse.
2. Clinical Pearls and Emerging Treatments:
- Targeted Therapies: New therapies targeting CD123 are showing promise in improving treatment outcomes with fewer adverse effects.
- Combination Approaches: Combining existing drugs with novel agents could enhance efficacy and reduce relapse rates.
- Stem Cell Transplantation: Advancements in stem cell transplants may offer better long-term remission prospects.
These emerging approaches offer hope for more effective, less toxic treatments for BPDCN.
Advertisement
Related to this article

Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders remaining event-free.

New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.

The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall survival.

The EGFR x LGR5 bispecific antibody petosemtamab demonstrated improved overall survival and overall response rate when added to pembrolizumab in head and neck squamous cell carcinoma.

COA urges Supreme Court review of Mississippi 340B contract pharmacy law, spotlighting PBM influence, drug access concerns, and calls for tighter oversight.

LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
3
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
4
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
5

